BL11A Phase III Study of Iressa? in Combination with Intravesical BCG versus Intravesical BCG Alone in High Risk Superficial Transitional Cell Carcinoma of the Bladder
BL12A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen
BL13A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer
PR10Randomized Trial of Radical Prostatectomy versus Brachytherapy for Patients With T1c or T2a N0 M0 Prostate Cancer
PR11A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer (START)
PR12Phase III Study of Neoadjuvant Docetaxel And Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy For High-Risk Localized Adenocarcinoma Of The Prostate (DART)
PR17Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET
PR19A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
PR2Treatment of Pathologic Stage C Carcinoma of the Prostate With Adjuvant Radiotherapy
PR20A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
PR21A Randomized Phase II Study of 177Lu-PSMA-617 vs Docetaxel in Patients with Metastatic Castration-Resistant Prostate Cancer and PSMA-Positive Disease
PR22DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized Very High-Risk Cancer of the Prostate.
A Randomized Phase III Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localized Prostate Cancer
PR7A Phase III Randomized Trial Comparing Intermittent Versus Continuous Androgen Suppression for Patients With Prostate-Specific-Antigen Progression in the Clinical Absence of Distant Metastases Following Radiotherapy for Prostate Cancer
PRC4Phase III Trial of Enzalutamide (NSC#766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer
PRP1A Double-Blind, Placebo-Controlled, Randomized Study of Combination Vitamin E, Selenium and Soy Protein Product in Subjects With High Grade Prostatic Intraepithelial Neoplasia
PRP1BAn Investigation of Molecular and Genetic Risk Factors Associated With Development of Prostate Cancer in Subjects With High Grade Prostatic Intraepithelial Neoplasia Treated With Placebo or Combination Vitamin E, Selenium and Soy Protein Product
Inventory
Show Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| GENITO-URINARY | BL11 | 41 | 3 | 21 | 23 |
| GENITO-URINARY | BL12 | 199 | 73 | 108 | 153 |
| GENITO-URINARY | BL13 | 82 | 44 | 14 | 50 |
| GENITO-URINARY | PR10 | 39 | 1 | 1 | 2 |
| GENITO-URINARY | PR11 | 180 | 82 | 66 | 115 |
| GENITO-URINARY | PR12 | 48 | 32 | 2 | 33 |
| GENITO-URINARY | PR17 | 204 | 0 | 0 | 0 |
| GENITO-URINARY | PR19 | Open Trial | 33 | 115 | 147 |
| GENITO-URINARY | PR2 | 81 | 0 | 7 | 7 |
| GENITO-URINARY | PR20 | Open Trial | 165 | 151 | 303 |
| GENITO-URINARY | PR21 | 224 | 0 | 0 | 0 |
| GENITO-URINARY | PR22 | 318 | 104 | 106 | 156 |
| GENITO-URINARY | PR7 | 1386 | 0 | 0 | 0 |
| GENITO-URINARY | PRC4 | 49 | 0 | 0 | 0 |
| GENITO-URINARY | PRP1 | 303 | 3 | 28 | 30 |
| GENITO-URINARY | PRP1B | 122 | 8 | 97 | 97 |
(Core size is 0.6 mm)
Show
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| GENITO-URINARY | BL11 | 41 | 0 | 0 |
| GENITO-URINARY | BL12 | 199 | 1 | 24 |
| GENITO-URINARY | BL13 | 82 | 0 | 0 |
| GENITO-URINARY | PR10 | 39 | 0 | 0 |
| GENITO-URINARY | PR11 | 180 | 1 | 8 |
| GENITO-URINARY | PR12 | 48 | 0 | 0 |
| GENITO-URINARY | PR17 | 204 | 0 | 0 |
| GENITO-URINARY | PR19 | Open Trial | 0 | 0 |
| GENITO-URINARY | PR2 | 81 | 0 | 0 |
| GENITO-URINARY | PR20 | Open Trial | 0 | 0 |
| GENITO-URINARY | PR21 | 224 | 0 | 0 |
| GENITO-URINARY | PR22 | 318 | 0 | 0 |
| GENITO-URINARY | PR7 | 1386 | 0 | 0 |
| GENITO-URINARY | PRC4 | 49 | 0 | 0 |
| GENITO-URINARY | PRP1 | 303 | 1 | 1 |
| GENITO-URINARY | PRP1B | 122 | 0 | 0 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| GENITO-URINARY | BL11 | 41 | 33 | 0 | 0 | 10 | 0 | 33 | 33 | 0 |
| GENITO-URINARY | BL12 | 199 | 157 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GENITO-URINARY | BL13 | 82 | 50 | 1 | 0 | 0 | 50 | 0 | 48 | 0 |
| GENITO-URINARY | PR10 | 39 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GENITO-URINARY | PR11 | 180 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
| GENITO-URINARY | PR12 | 48 | 0 | 0 | 0 | 0 | 0 | 29 | 0 | 0 |
| GENITO-URINARY | PR17 | 204 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| GENITO-URINARY | PR19 | Open Trial | 73 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GENITO-URINARY | PR2 | 81 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GENITO-URINARY | PR20 | Open Trial | 348 | 0 | 0 | 0 | 347 | 0 | 1 | 0 |
| GENITO-URINARY | PR21 | 224 | 192 | 0 | 0 | 0 | 192 | 0 | 0 | 0 |
| GENITO-URINARY | PR22 | 318 | 165 | 0 | 0 | 0 | 172 | 172 | 0 | 0 |
| GENITO-URINARY | PR7 | 1386 | 289 | 0 | 0 | 0 | 6 | 877 | 0 | 0 |
| GENITO-URINARY | PRC4 | 49 | 38 | 0 | 0 | 0 | 38 | 0 | 0 | 0 |
| GENITO-URINARY | PRP1 | 303 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| GENITO-URINARY | PRP1B | 122 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |